Dyne Therapeutics, Inc. DYN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $753.1M+59.5% | $893.37M+105% | $573.61M+7.8% | $485.04M-20.2% | $472.26M+73.6% | ||
| $219.05M+6.7% | $217.19M+5.0% | $218.28M+14.0% | $198.89M+16.6% | $205.24M+13.1% | ||
| $1.02B+48.1% | $1.13B+70.9% | $806.26M+9.5% | $697.95M-11.9% | $689.5M+41.3% | ||
| $23.68M+312% | $24.03M+345% | $23.97M+390% | $5.68M+13.0% | $5.75M+25.5% | ||
| $1.08B+49.8% | $1.19B+71.7% | $867.06M+12.8% | $728.99M-11.7% | $721.07M+38.1% | ||
| $10.78M+53.6% | $8.08M+23.2% | $12.06M+95.9% | $14.02M+642% | $7.02M-2.7% | ||
| $51.25M+51.3% | $50.63M+19.8% | $59.85M+38.3% | $41.47M+39.4% | $33.88M+51.5% | ||
| $149.38M— | —— | —— | —— | —— | ||
| $214.9M+312% | $214.83M+250% | $175.28M+177% | $157.55M+211% | $52.1M+17.8% | ||
| $16K+45.5% | $16K+60.0% | $14K+40.0% | $11K+10.0% | $11K+22.2% | ||
| -$1.52B-42.4% | -$1.4B-47.0% | -$1.28B-49.3% | -$1.18B-54.1% | -$1.07B-52.6% | ||
| $865.06M+29.3% | $972.13M+54.3% | $691.78M-1.9% | $571.45M-26.3% | $668.97M+39.9% | ||
| $1.08B+49.8% | $1.19B+71.7% | $867.06M+12.8% | $728.99M-11.7% | $721.07M+38.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dyne Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 19.92 — current assets exceed current liabilities.
- Where does Dyne Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.